S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
S&P 500   3,360.47 (+0.27%)
DOW   27,791.44 (+1.30%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
Log in

NASDAQ:GERNGeron Stock Price, Forecast & News

$1.64
-0.04 (-2.38 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.62
Now: $1.64
$1.69
50-Day Range
$1.59
MA: $1.96
$2.19
52-Week Range
$0.75
Now: $1.64
$2.40
Volume1.48 million shs
Average Volume2.50 million shs
Market Capitalization$333.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
Read More
Geron logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$0.68 per share

Profitability

Net Income$-68,550,000.00
Net Margins-19,251.64%

Miscellaneous

Employees45
Market Cap$333.44 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$1.64
-0.04 (-2.38 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Geron (NASDAQ:GERN) Frequently Asked Questions

How has Geron's stock been impacted by COVID-19 (Coronavirus)?

Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GERN shares have increased by 59.2% and is now trading at $1.64.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Geron?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Geron
.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Geron
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.06). Geron had a negative net margin of 19,251.64% and a negative return on equity of 56.15%.
View Geron's earnings history
.

What price target have analysts set for GERN?

6 equities research analysts have issued 1-year price objectives for Geron's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate Geron's stock price to reach $3.50 in the next year. This suggests a possible upside of 113.4% from the stock's current price.
View analysts' price targets for Geron
.

Has Geron been receiving favorable news coverage?

Press coverage about GERN stock has been trending very positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Geron earned a news sentiment score of 3.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Geron
.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

Who are Geron's key executives?

Geron's management team includes the following people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 69, Pay $1.15M)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 51, Pay $687.17k)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 56, Pay $705.69k)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 56, Pay $673.36k)
  • Dr. Aleksandra Rizo M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 45, Pay $968.2k)

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by many different retail and institutional investors. Top institutional investors include Swiss National Bank (0.34%), Cambridge Investment Research Advisors Inc. (0.18%), Virtus ETF Advisers LLC (0.11%), WINTON GROUP Ltd (0.07%), New York State Common Retirement Fund (0.07%) and Raymond James Financial Services Advisors Inc. (0.06%). Company insiders that own Geron stock include Elizabeth G O'farrell, Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield.
View institutional ownership trends for Geron
.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Geron
.

Which major investors are buying Geron stock?

GERN stock was acquired by a variety of institutional investors in the last quarter, including Swiss National Bank, WINTON GROUP Ltd, Cambridge Investment Research Advisors Inc., ProShare Advisors LLC, New York State Common Retirement Fund, SG Americas Securities LLC, Arizona State Retirement System, and Creative Planning.
View insider buying and selling activity for Geron
.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.64.

How big of a company is Geron?

Geron has a market capitalization of $333.44 million and generates $460,000.00 in revenue each year. The biopharmaceutical company earns $-68,550,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Geron employs 45 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.